🔎 Trials Near Me

Home › Opioid Overdose › NCT06732596

Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents

Recruiting

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Diagnosis of Opioid Use Disorder (OUD)
* Within 30 days of intake at recruitment site (BMC OBAT)
* Possession of a smartphone that has minimum requirements
* English-speaking and reading
* Willing to release electronic health record (EHR) data
* Able to provide at least two alternate contacts who usually know how to get in touch with them
* Currently prescribed buprenorphine from an outpatient clinic

Exclusion Criteria:

* Incarceration anticipated within 12 months of enrollment
* Inability to comprehend the study protocol, defined as failing three times to answer correctly a set of questions during the consent process
* Inability to use the ECA app (i.e., due to markedly limited visual or auditory acuity or motor function required to interact with the ECA)

About the study

This study aims to improve retention in buprenorphine treatment, a medication used for opioid use disorder, through the use of a smartphone-delivered recovery support intervention. The intervention involves an Embodied Conversational Agent (ECA), a virtual, animated computer agent designed to simulate natural face-to-face conversations. ECAs have been shown to help individuals manage their healthcare in other settings, and this study seeks to evaluate their potential in supporting patients on medication for opioid use disorder (MOUD).

What is being tested

Sponsor: Boston Medical Center · Participants: 100 · Started: Oct 30, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06732596

Locations in the U.S.

MassachusettsOffice-Based Addiction Treatment (OBAT) Clinic, BMC, Boston

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.